Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
DICIPLE trial (nivolumab): what clinicians have said so far
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
- NCT03469960 ↗
- Completed
- Intergroupe Francophone de Cancerologie Thoracique
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on DICIPLE (nivolumab plus ipilimumab in PD-L1-positive stage IV non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DICIPLE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 13 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer Metastatic
- Interventions
- Ipilimumab; Nivolumab
- Arms
- Arm A : standard treatment · Active comparator
- Arm B : experimental arm · Experimental
- Enrollment
- 265
- Primary outcomes
- Progression Free Survival (PFS1)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Start
- May 2, 2018
- Primary completion
- Nov 8, 2023
- Results posted
- No
- Registry record
- NCT03469960 · updated Nov 18, 2025